## MAYO CLINIC Whole Exome Sequencing: LABORATORIES Ordering Checklist

Instructions: Select the box for the test requested on the patient (proband) and complete the corresponding ordering checklist.	
□ Whole Exome Sequencing for Hereditary Disorders or □ Whole Exome and Mitochondrial Genome Sequencing	
☐ For the patient (proband), order WESDX / Whole Exome Sequencing for Hereditary Disorders, Varies or WESMT / Whole Exome and Mitochondrial Genome Sequencing, Varies.	
□ For each family member specimen that will be submitted as a comparator, order CMPRE / Family Member Comparator Specimen for Exome Sequencing, Varies. Separate orders need to be placed for each family member. Biological parents are the preferred family member comparators; see test catalog for additional information.	
□ Collect patient (proband) and family member specimens. Label specimens with full name and birth date. Do not label family members' specimens with the proband's name. See test catalog for specimen requirements.	
☐ Complete the Patient Information form on pages 2–4 (required for all clients).	
☐ Complete the signature sections of the Informed Consent on page 7 (required for New York State clients).	
☐ If the patient wishes to opt out of receiving secondary findings or change the DNA storage selection, select the appropriate boxes on page 7.	
☐ Attach clinic notes from specialists relevant to patient's clinical features.	
☐ Attach pedigree.	
□ Send paperwork, clinic notes, and pedigree along with specimens. If not sent with the specimen, fax a copy of the paperwork to 507-284-1759, Attn: WES Genetic Counselors.	
☐ Whole Exome Sequencing Reanalysis	
☐ For the patient (proband), order WESR / Whole Exome Sequencing Reanalysis, Varies.	
□ Call Mayo Clinic Laboratories at 800-533-1710 and request that WESR is added on to remaining DNA specimen from the original whole exome sequencing test. If the laboratory determines that the patient previously opted out of DNA storage or the specimen was depleted, a new specimen will be requested. See test catalog for specimen requirements.	
☐ Complete the following sections of the Whole Exome Sequencing paperwork:	
<ul> <li>Patient (Proband) Information (page 2)</li> </ul>	
<ul> <li>Provide reason for reanalysis request in Reason for Testing (page 2)</li> </ul>	
<ul> <li>Provide new information in Suspected Diagnoses (page 3), Patient (Proband) Clinical Evaluations (page 3), and Patient (Proband) Clinical Features (page 4)</li> </ul>	3
☐ Attach clinic notes and/or a pedigree with any relevant new clinical or family history information.	

Questions: Call with any questions and ask to speak to a WES genetic counselor at 507-293-7299.

 $\ \square$  Fax the paperwork, clinic notes, and pedigree to 507-284-1759, Attn: WES Genetic Counselors.



# MAYO CLINIC | Whole Exome Sequencing: LABORATORIES | Patient Information

Instructions: Provide the requested information below for appropriate interpretation of the Whole Exome Sequencing test result. In addition, submit relevant clinic notes and pedigree.

Patient (Proband) Information (required)			
Patient Name (Last, First, Middle)	Medical Record No.	Birth Date (mm-dd-yyyy)	Sex ☐ Male ☐ Female
Referring Provider Name (Last, First)		Phone	Fax*
Other Contact/Geneticist/Genetic Counselor (Last, First)		Phone	Fax*
Reason for Testing	*Fax number given must be	from a fax machine that complied	 es with applicable HIPAA regulations
Biological Family Member Information Only complete info a comparator sample. The priority should always be to include both parents to discuss sending more than 2 comparators or comparators that are not fir	as comparators, if poss		
		be received within 3 week hat time with specimens t	
Name (Last, First, Middle)	Medical Record No.	Birth Date (mm-dd-yyyy)	Sex ☐ Male ☐ Female
Relationship to Proband  Mother Father Full sibling Maternal half-sibling  Other relatives are accepted on a case-by-case basis; contact a go	☐ Paternal half-siblinenetic counselor at 507-	-	re ordering testing:
Does this relative share any relevant clinical features or clinical history with	· 	☐ Yes If Yes, descril	
		be received within 3 week hat time with specimens t	
Name (Last, First, Middle)	Medical Record No.	Birth Date (mm-dd-yyyy)	Sex  ☐ Male ☐ Female
Relationship to Proband  Mother Father Full sibling Maternal half-sibling  Other relatives are accepted on a case-by-case basis; contact a go	☐ Paternal half-sibli enetic counselor at 507-	-	re ordering testing:
Does this relative share any relevant clinical features or clinical history with	n the patient? $\ \square$ No	☐ Yes If Yes, descril	be:
· · · ·		be received within 3 week hat time with specimens t	
Name (Last, First, Middle)	Medical Record No.	Birth Date (mm-dd-yyyy)	Sex ☐ Male ☐ Female
Relationship to Proband  Mother Father Full sibling Maternal half-sibling  Other relatives are accepted on a case-by-case basis; contact a go	☐ Paternal half-siblinenetic counselor at 507-	-	re ordering testing:
Does this relative share any relevant clinical features or clinical history with	n the patient? $\ \square$ No	☐ Yes If Yes, descril	be:

Patient Name (Last, First, Middle)						Birth Date (mm-dd-yyyy)
Ancestry						
☐ African/African American	☐ East A		☐ Latino/Latina	☐ South Asian		se not to disclose
☐ Ashkenazi Jewish	☐ Europe	ean	☐ Middle Eastern	☐ None of the above	□ Unkno	own
History of Consanguinity						
$\square$ No $\square$ Yes; relationship	details:					
Suspected Diagnoses	s/Genes	of I	nterest List suspected d	iagnoses or specific genes th	at you would	like considered for this evaluation.
Patient (Proband) Cline regarding the specific tests and						
Karyotype	□ Normal		Abnormal:			
Chromosomal Microarray	☐ Normal		Abnormal:			
Gene Sequencing/Panel*	□ Normal		Abnormal:			
Methylation/UPD*	□ Normal		Abnormal:			
Mitochondrial DNA*	□ Normal		Abnormal:			
Metabolic Work-up*	☐ Normal					
Brain MRI	☐ Normal	1				
Brain Spectroscopy	□ Normal		Abnormal:			
Electroencephalogram (EEG)	□ Normal		Abnormal:			
Echocardiogram	□ Normal		Abnormal:			
Electrocardiogram (ECG/EKG)	□ Normal		Abnormal:			
Skeletal Survey	□ Normal		Abnormal:			
Renal Imaging	☐ Normal		Abnormal:			
Muscle Biopsy	☐ Normal		Abnormal:			
Electromyogram (EMG)	□ Normal		Abnormal:			
Ophthalmology Exam	☐ Normal					
Audiology Evaluation	□ Normal		Abnormal:			
*Describe Details	,					

Page 3 of 7 MC1235-222rev0322

Patient (Proband) Clinical Fe his information is required to facilitate in Perinatal History Beha			Birth Date (mm-dd-yyyy)
arinatal History Roha		atient (proband) and provide addition	onal descriptions, if available.
Intrauterine growth restriction	tention-deficit/Hyperactivity disorder utism spectrum disorder ehavioral abnormality; specify below bsessive-compulsive disorder leep disturbance romuscular bnormality of brain morphology; pecify below	Hearing  Conductive hearing loss  Mixed hearing loss  Sensorineural hearing loss  Dphthalmologic  Esotropia  High myopia  Nystagmus  Ptosis  Strabismus  Cardiovascular  Aortic dilatation/dissection  Arrhythmia  Atrial septal defect  Cardiomyopathy  Patent ductus arteriosus  Patent foramen ovale  Ventricular septal defect  Gastrointestinal  Abnormal GI motility; specify below  Abnormality of the liver; specify below  Dysphagia  Feeding difficulties  Gastrointestinal inflammation  Nausea and vomiting  Splenomegaly	Genitourinary  Abnormal external genitalia  Cliteromegaly  Cryptorchidism  Hydronephrosis  Renal malformation  Skin/Hair/Dental  Abnormal skin; specify below  Café-au-lait spot; specify below  Dental abnormalities; specify below  Hemangioma  Hyperpigmentation  Endocrine  Adrenal abnormality  Hypothyroidism  Pituitary gland abnormality  Thyroid gland abnormality  Hematologic/Immunologic  Anemia  Bruising susceptibility  Immunodeficiency  Recurrent infections  Cancer/Neoplastic  Specify age of onset and tumor type:

Page 4 of 7 MC1235-222rev0322





### MAYO CLINIC | Whole Exome Sequencing: LABORATORIES | Informed Consent

This form is provided to ensure that you are informed about a genetic test called whole exome sequencing. Whole exome sequencing is a complex genetic test. Genetic counseling is recommended to help you more fully understand the risks and benefits associated with this test. It is your choice whether or not to have this test.

#### What is Whole Exome Sequencing?

- Whole exome sequencing is a test that detects changes (variants) in a patient's genetic code (DNA) which may be causing a genetic disorder. Humans have approximately 20,000 genes. Variants in certain important portions of these genes, the exons (coding regions), account for the majority of the variants that cause genetic disorders. Taken together, all of our exons make up the "exome."
- The goal of whole exome sequencing is to identify genetic variants that may provide or confirm a specific diagnosis for a patient.

#### **How is Whole Exome Sequencing performed?**

- · A blood draw or other procedure will be required to obtain samples from all individuals undergoing testing. DNA is obtained from the samples and sequenced to identify genetic variants.
- The laboratory evaluates certain characteristics of each variant (such as the type of genetic change, whether family members have this change, and how common it is in the general population) in order to determine whether it could cause a genetic disorder in a patient.

#### What are the potential benefits of Whole Exome Sequencing?

- Genetic variants may be detected that explain a patient's clinical features and provide a diagnosis.
- Establishing a diagnosis may allow for a better prediction of the outcome or course of a disorder. It may also help to determine the best medical management for a patient, such as surveillance, treatment, or preventive measures.
- Identification of a diagnosis may also allow for a more accurate risk estimate and/or testing of at-risk or affected family members.

#### What are the potential risks of Whole Exome Sequencing?

- If a disease-causing variant is found and a specific diagnosis is made, it may not change the medical management that was previously recommended. There also may not be a treatment available for the disorder.
- In some cases, a health care provider may recommend additional tests to better understand the results from whole exome sequencing.
- Other possible risks, such as those associated with financial/insurance considerations, psychological effects, and implications for family members should be discussed with your health care provider.

#### What are the limitations of Whole Exome Sequencing?

- Whole exome sequencing will not establish a diagnosis for all patients who have the test.
- At this time, greater than 95% of the exome can be sequenced well enough to be interpreted. This means that about 5% of the exome cannot be analyzed. If a genetic variant exists in an unanalyzed region, it would not be detected.
- Because whole exome sequencing focuses on the most important regions of genes (the exons, or coding regions), variants in other areas of genes may be missed. Certain types of variants may not be detected by this test.
- Scientific understanding of the role of genes and variants in human diseases is not complete. Therefore, the significance of some variants that are found may not be known. Patients are encouraged to contact their health care provider for updates regarding their test results, as understanding may change with time.
- The laboratory's interpretation is based upon the accuracy of the clinical information and family history provided by the ordering health care provider. If pertinent information is not provided, this may affect whether certain variants are reported.

#### What types of test results will the laboratory report?

- Variants in genes associated with the patient's clinical features: Variants in genes known to cause conditions that have features which overlap with the patient's clinical features will be reported (including carrier status for recessive conditions). Variants in these genes will be reported if they are known or expected to cause the genetic condition (pathogenic or likely pathogenic). Variants of uncertain significance in these genes will also be reported.
- Variants in genes of uncertain significance: Variants may be found in genes that are suspected, but not certain, to play a role in human disease. Variants in these genes of uncertain clinical significance may be reported if there is suspicion that they are related to a patient's clinical features.

Page 5 of 7 MC1235-222rev0322

Patient Name (Last, First, Middle)	Birth Date (mm-dd-yyyy)

#### Will secondary findings be reported?

- Secondary findings are variants that are unrelated to the reason that a patient is having whole exome sequencing. Individuals can choose to not
  receive secondary findings by opting out on the following page. Note that if the proband opts out, secondary findings will not be reported
  for any family member.
- Secondary findings will be reported if they are in one of the genes currently recommended by the American College of Medical Genetics and Genomics (ACMG), and only if they are known or expected to cause disease. Variants of uncertain significance will not be reported in these genes, unless they are associated with the patient's clinical features.
- Rarely, findings outside of these genes may implicate another predisposition or presence of active disease. These findings will be carefully reviewed
  to determine whether or not they will be reported.
- Knowledge of a person's risk for these conditions can help to determine the medical actions available to maintain that person's health, such as screening for cancer or specific heart conditions.
- These results may lead to increased anxiety or worry. They may also result in additional medical interventions.

#### Why it is recommended that family members should be tested and what types of test results will they receive?

- Interpretation of genetic variants is more accurate when the laboratory is able to compare the results between the patient and their family members.
- Based on published reports, the chance of finding a diagnosis is highest when samples are submitted from both biological parents. However, the patient alone or in combination with other family members can be submitted.
- Family members will not receive their own full test results. However, if the patient's reported genetic variants are identified in another family member, this will be indicated in the patient's report. Family members may learn about a diagnosis of a genetic condition, increased risk for health concerns, or carrier status for a recessive condition.
- Variants present in family members that are absent from the patient will not be reported.

#### What else could whole exome sequencing results reveal about family members?

- It is possible to uncover that a parent or other family member is unrelated to the patient, or that relationships are not as described due to mis-attributed paternity, maternity, or adoption. In this situation, the ordering provider will be notified and options will be discussed.
- In some cases, results may suggest that the parents of a patient are biologically related, such as first cousins or another familial relationship.

#### What types of test results will the laboratory not report?

- Variants that are benign (not disease causing) or likely benign will not be reported.
- Variants in genes associated with conditions that are not related to a patient's reported clinical features will not be reported, with the possible
  exception of the secondary findings described above.

#### What does a negative whole exome sequencing report mean?

A negative report means that no variants were reported and an explanation for the patient's clinical features was not identified. However, because
of the testing limitations noted above, there may still be a genetic explanation for a patient's features that was not identified by this test.

#### How will the test results become available?

- The laboratory will release a patient's test report directly to the ordering health care provider and it will become part of the patient's medical record.
- Requests for the raw data obtained from whole exome sequencing should be directed to the laboratory. A separate fee may apply. The laboratory is
  not responsible for providing software or other tools needed to visualize, filter, or interpret this data.

#### Will my test results be shared with databases or researchers?

- Mayo Clinic is an active participant in the National Institutes of Health-funded Clinical Genome Resource (ClinGen) and shares information about genetic variants identified through clinical genetic testing with publicly available databases, such as ClinVar and Matchmaker Exchange.
- No patient-identifying information (ie, name, birth date) is shared.
- Genomic data sharing enables health care providers, clinical laboratories, and researchers to share experiences. This can lead to improved interpretations of genetic test results.

#### What will happen to my DNA after testing is complete?

- The laboratory does not guarantee indefinite storage of patient samples and may discard them within 60 days of test completion, in accordance with state-specific regulations.
- Any sample remaining after testing is complete may be used for internal laboratory quality control or research purposes, after the removal of
  patient identifiers such as name and birth date. You may request that your DNA sample not be used for these purposes by indicating this
  preference on the next page.
- At this time, it is not standard practice for the laboratory to systematically re-review patient results or previous variant classifications. However,
  due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur,
  the laboratory will recontact the healthcare provider to discuss the new findings or classification of previously reported variants; the laboratory may
  issue an amended report.

Patient Name (Last, First, Middle)	Birth I	Date (mm-dd-yyyy)
Informed Consent for Whole Exome Sequencing Sign	nature Page	
<b>Instructions: Informed consent is required for New York clients.</b> My signathat the genetic analysis performed by Mayo Clinic Laboratories in no way gramily members.		
Secondary findings:		
<ul> <li>Patient (proband): Checking the "Opt out of secondary findings" box to secondary findings genes published by ACMG and will not report them If the patient (proband) opts out, secondary findings will not be reported page is not returned, opt in will be assumed.</li> </ul>	unless the variant is in a gene related to the patie	nt's clinical features.
<ul> <li>Family member comparators: Opting in to secondary findings means absence of these variants in the family member will be stated on the p Checking the "Opt out of secondary findings" box below means that if these variants in the family member will not be stated. If the boxes are</li> </ul>	roband's report (family members will not receive t secondary findings are reported in the proband, th	heir own separate report). he presence or absence of
Patient (Proband) Signature My signature below acknowledges my voluntary participation in this test for m	yself or my child.	
Patient/Guardian Signature	Date (mm-dd-yyyy)	□ Opt out of
Parent/Guardian Printed Name (Last, First, Middle)	Guardian Relationship to Patient	secondary findings

Patient/Guardian Signature  The state of the	Date (mm-dd-yyyy)	□ Opt out of
Parent/Guardian Printed Name (Last, First, Middle)	Guardian Relationship to Patient	secondary findings
Family Member Signatures Only fill out information for family members whose specimens are being sent as comparator	rs.	

Unly fill out information for family members whose specimens are being s	sent as comparators.	
Family Member 1 Signature	Date (mm-dd-yyyy)	□ Opt out of
Family Member 1 Printed Name (Last, First, Middle)	Birth Date (mm-dd-yyyy)	secondary findings
Family Member 2 Signature	Date (mm-dd-yyyy)	□ Opt out of
Family Member 2 Printed Name (Last, First, Middle)	Birth Date (mm-dd-yyyy)	secondary findings
Family Member 3 Signature	Date (mm-dd-yyyy)	□ Opt out of
Family Member 3 Printed Name (Last, First, Middle)	Birth Date (mm-dd-yyyy)	secondary findings

### **Provider/Genetic Counselor Signature**

I have explained the above information regarding whole exome sequencing to this individual. I have addressed the limitations outlined above and have answered all questions to the best of my ability.

Provider/Genetic Counselor Signature	Date (mm-dd-yyyy)	Provider/Genetic Counselor Printed Name (Last, First)
<b>&gt;</b>		

#### **DNA storage:**

- All clients residing outside of New York: Checking the "Opt out of DNA storage" box below means that samples for the proband and any family member comparators will be destroyed upon completion of this test, and will not be used for research or quality assurance performed in the laboratory. Should reanalysis be requested in the future, new sample(s) will be required. If the box below is not checked or this page is not returned, opt in will be assumed.
  - □ Opt out of DNA storage
- New York clients: Checking the "New York clients: permission to retain remaining sample(s)" box below means that permission is given to retain any remaining samples for the proband and any family member comparators longer than 60 days after the completion of testing, and can be used as de-identified samples for research or quality assurance performed in the laboratory. If the box is not checked, all samples from New York clients will be disposed of 60 days after testing is complete and will not be used for research or quality assurance purposes. Should reanalysis be requested in the future, new sample(s) will be required.
  - ☐ New York clients: permission to retain remaining sample(s)

Page 7 of 7 MC1235-222rev0322